Cyclosporine A treatment of leprosy patients with chronic neuritis is associated with pain control and reduction in antibodies against nerve growth factor.

OBJECTIVES Chronic neuritis (CN) is still a major problem in leprosy and is difficult to manage in patients who do not respond well to prednisone. In this study we (i) evaluate the efficacy of cyclosporine A (CyA) in controlling CN patients, and (ii) analyse the presence of anti-NGF antibodies in the sera of leprosy patients, and their behaviour during CyA treatment. DESIGN This was an open, prospective, non-comparative study. Sixty-seven leprosy patients in three different institutions in Pará, Brazil were studied from January, 2001 to January, 2004. Of these, 47 had no CN and 20 were leprosy patients suffering from CN and taking at least 40 mg/day prednisone to control nerve impairment and pain. Patients received 12 months reducing course CyA starting at 5 mg/kg per day. The outcome measure was sensory impairment, assessed using Semmes-Weinstein monofilament examination (SWME), muscular force and spontaneous or palpation-related pain. RESULTS Antibodies against NGF were detected in the sera of leprosy patients, which may explain the depletion of NGF in leprosy contributing to neuritis, inflammation and loss of cutaneous nociception. The levels of these antibodies in CN patients were slightly lower than in patients with no CN. However, anti-NGF titres in CN patients treated with CyA were lowered to levels similar to those in the normal subjects. There was also improvement in sensory impairment, muscular force and pain. CONCLUSIONS These data suggest that anti-NGF antibodies are present in the sera of leprosy patients and may influence the outcome of neuritis, and that CyA might be a useful drug in controlling nerve impairment and pain in leprosy patients.

[1]  D. Lockwood,et al.  Clinical outcomes in a randomized controlled study comparing azathioprine and prednisolone versus prednisolone alone in the treatment of severe leprosy type 1 reactions in Nepal. , 2004, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[2]  R. Gold,et al.  Immunotherapy in autoimmune neuromuscular disorders , 2003, The Lancet Neurology.

[3]  T. Lundeberg,et al.  NGF modulates CGRP synthesis in human B-lymphocytes: a possible anti-inflammatory action of NGF? , 2002, Journal of Neuroimmunology.

[4]  P. Byass,et al.  The pattern of leprosy-related neuropathy in the AMFES patients in Ethiopia: definitions, incidence, risk factors and outcome. , 2000, Leprosy review.

[5]  J. Richardus,et al.  The treatment of acute nerve function impairment in leprosy: results from a prospective cohort study in Bangladesh. , 2000, Leprosy review.

[6]  S. Matsuda,et al.  Mechanisms of action of cyclosporine. , 2000, Immunopharmacology.

[7]  P. Anand,et al.  Do nerve growth factor-related mechanisms contribute to loss of cutaneous nociception in leprosy? , 2000, Pain.

[8]  A. Marconi,et al.  Autocrine nerve growth factor in human keratinocytes. , 2000, Journal of dermatological science.

[9]  Z. Xiang,et al.  Human mast cells express functional TrkA and are a source of nerve growth factor , 1997, European journal of immunology.

[10]  E. H. Bernink,et al.  Study on the detection of leprosy reactions and the effect of prednisone on various nerves, Indonesia. , 1997, Leprosy review.

[11]  S. Skaper,et al.  Nerve growth factor: from neurotrophin to neurokine , 1996, Trends in Neurosciences.

[12]  S. Skaper,et al.  Update of the NGF saga , 1995, Journal of the Neurological Sciences.

[13]  B. Singhal,et al.  Depletion of nerve growth factor in leprosy , 1994, The Lancet.

[14]  B. Naafs,et al.  Cyclosporin A treatment in reversal reaction. , 1994, Tropical and geographical medicine.

[15]  D. Hurez,et al.  Natural autoantibodies against the nerve growth factor in autoimmune diseases , 1993, Journal of Neuroimmunology.

[16]  D. Lockwood,et al.  Clinical features and outcome of reversal (type 1) reactions in Hyderabad, India. , 1993, International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association.

[17]  P. Ashby,et al.  Changes in nerves and neuropeptides in skin from 100 leprosy patients investigated by immunocytochemistry , 1989, The Journal of pathology.

[18]  R. Miller,et al.  Treatment of chronic erythema nodosum leprosum with cyclosporine A produces clinical and immunohistologic remission. , 1987, International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association.

[19]  O. Parkash,et al.  Isolation and analysis of circulating immune complexes in leprosy. , 1984, Clinical immunology and immunopathology.

[20]  V. Sharma,et al.  Serum immunoglobulins an autoantibodies during and after erythema nodosum leprosum (ENL). , 1982, International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association.

[21]  Gaitondé Bb,et al.  A study of autonomic functions in leprosy. , 1982 .

[22]  B. Gaitondé,et al.  A study of autonomic functions in leprosy. , 1982, Leprosy in India.

[23]  R. Levi‐montalcini,et al.  Nerve growth factor. , 1975, Science.

[24]  E. Shooter,et al.  Nerve growth factor (third of three parts). , 1977 .

[25]  L. Greene,et al.  Establishment of a noradrenergic clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth factor. , 1976, Proceedings of the National Academy of Sciences of the United States of America.

[26]  H. Arnold,et al.  Leprosy: Diagnosis and Management , 1973 .

[27]  V. Hamburger,et al.  In vitro experiments on the effects of mouse sarcomas 180 and 37 on the spinal and sympathetic ganglia of the chick embryo. , 1954, Cancer research.